The ANGPTL3 monoclonal antibody, SHR-1918, reduces LDL-C and TG when added to standard lipid lowering therapy in patients at moderate or higher risk of atherosclerotic cardiovascular disease, according to results of a Phase 2 study presented at the congress and published in the Journal of the American College of Cardiology.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
